Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Dengue human infection models supporting drug development.

Whitehorn J, Van VC, Simmons CP.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S66-70. doi: 10.1093/infdis/jiu062.

2.

Dengue human infection models to advance dengue vaccine development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.

3.

Dengue human infection model performance parameters.

Endy TP.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S56-60. doi: 10.1093/infdis/jiu112.

4.

Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.

Whitehorn J, Yacoub S, Anders KL, Macareo LR, Cassetti MC, Nguyen Van VC, Shi PY, Wills B, Simmons CP.

PLoS Negl Trop Dis. 2014 Aug 28;8(8):e3025. doi: 10.1371/journal.pntd.0003025. eCollection 2014 Aug. Review.

5.

The human dengue challenge experience at the Walter Reed Army Institute of Research.

Lyons AG.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S49-55. doi: 10.1093/infdis/jiu174.

PMID:
24872396
6.

Biological characteristics of dengue virus and potential targets for drug design.

Qi RF, Zhang L, Chi CW.

Acta Biochim Biophys Sin (Shanghai). 2008 Feb;40(2):91-101. Review.

7.

Dengue human infection model: introduction.

Cassetti MC, Thomas SJ.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S37-9. doi: 10.1093/infdis/jiu061. No abstract available.

8.

Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Züst R, Toh YX, Valdés I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillén G, Kalinke U, Shi PY, Fink K.

J Virol. 2014 Jul;88(13):7276-85. doi: 10.1128/JVI.03827-13. Epub 2014 Apr 16.

9.

DHIM supporting immunologic investigations and the identification of immune correlates of protection.

Rothman AL.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S61-5. doi: 10.1093/infdis/jiu111.

10.

Dengue vaccine: opportunities and challenges.

Hatch S, Mathew A, Rothman A.

IDrugs. 2008 Jan;11(1):42-5. Review.

PMID:
18175262
11.

Investigational drugs in early development for treating dengue infection.

Beesetti H, Khanna N, Swaminathan S.

Expert Opin Investig Drugs. 2016 Sep;25(9):1059-69. doi: 10.1080/13543784.2016.1201063. Epub 2016 Jun 24. Review.

PMID:
27322111
12.

Pharmacological intervention for dengue virus infection.

Lai JH, Lin YL, Hsieh SL.

Biochem Pharmacol. 2017 Apr 1;129:14-25. doi: 10.1016/j.bcp.2017.01.005. Epub 2017 Jan 16. Review.

PMID:
28104437
13.

Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting.

Lam SK, Burke D, Capeding MR, Chong CK, Coudeville L, Farrar J, Gubler D, Hadinegoro SR, Hanna J, Lang J, Lee HL, Leo YS, Luong CQ, Mahoney R, McBride J, Mendez-Galvan J, Ng LC, Nimmannitya S, Ooi EE, Shepard D, Smit J, Teyssou R, Thomas L, Torresi J, Vasconcelos P, Wirawan DN, Yoksan S.

Vaccine. 2011 Nov 28;29(51):9417-22. doi: 10.1016/j.vaccine.2011.08.047. Epub 2011 Aug 22.

14.

The role of the mosquito in a dengue human infection model.

Mores CN, Christofferson RC, Davidson SA.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S71-8. doi: 10.1093/infdis/jiu110.

15.

Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.

Frias-Staheli N, Dorner M, Marukian S, Billerbeck E, Labitt RN, Rice CM, Ploss A.

J Virol. 2014 Feb;88(4):2205-18. doi: 10.1128/JVI.03085-13. Epub 2013 Dec 11.

16.

Current Status of Dengue Therapeutics Research and Development.

Low JG, Ooi EE, Vasudevan SG.

J Infect Dis. 2017 Mar 1;215(suppl_2):S96-S102. doi: 10.1093/infdis/jiw423. Review.

17.

Towards antiviral therapies for treating dengue virus infections.

Kaptein SJ, Neyts J.

Curr Opin Pharmacol. 2016 Oct;30:1-7. doi: 10.1016/j.coph.2016.06.002. Epub 2016 Jun 28. Review.

PMID:
27367615
18.

Drugs for dengue: a patent review (2010-2014).

Beesetti H, Khanna N, Swaminathan S.

Expert Opin Ther Pat. 2014 Nov;24(11):1171-84. doi: 10.1517/13543776.2014.967212. Epub 2014 Oct 6. Review.

PMID:
25283170
19.

Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas.

Letson GW, Singhasivanon P, Fernandez E, Abeysinghe N, Amador JJ, Margolis HS, Edelman R.

Hum Vaccin. 2010 Oct;6(10):802-9. Epub 2010 Oct 1. Review.

20.

Models of the impact of dengue vaccines: a review of current research and potential approaches.

Johansson MA, Hombach J, Cummings DA.

Vaccine. 2011 Aug 11;29(35):5860-8. doi: 10.1016/j.vaccine.2011.06.042. Epub 2011 Jun 23. Review.

Supplemental Content

Support Center